perifosine + lenalidomide + dexamethasone

This combination consists of **perifosine** (an oral Akt inhibitor), **lenalidomide** (an immunomodulatory drug), and **dexamethasone** (a synthetic glucocorticoid). It is being investigated as an all-oral regimen primarily for relapsed or refractory multiple myeloma. Perifosine inhibits growth and survival pathways in myeloma cells by blocking Akt signaling. Lenalidomide enhances immune system activity against tumor cells and disrupts the tumor microenvironment. Dexamethasone has antitumor, anti-inflammatory, and immunosuppressive properties. The combination is designed to maximize anti-myeloma activity via complementary mechanisms and has shown promising efficacy and manageable toxicity in early-phase trials[1][2][4][6][8].